176 related articles for article (PubMed ID: 38226414)
1. Enhancer-activated RET confers protection against oxidative stress to KMT2A-rearranged acute myeloid leukemia.
Frett B; Stephens KE; Koss B; Melnyk S; Farrar J; Saha D; Roy Choudhury S
Cancer Sci; 2024 Mar; 115(3):963-973. PubMed ID: 38226414
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic regulation of protein translation in KMT2A-rearranged AML.
Lenard A; Xie HM; Pastuer T; Shank T; Libbrecht C; Kingsley M; Riedel SS; Yuan ZF; Zhu N; Neff T; Bernt KM
Exp Hematol; 2020 May; 85():57-69. PubMed ID: 32437908
[TBL] [Abstract][Full Text] [Related]
3. KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia.
Kanayama T; Imamura T; Kawabe Y; Osone S; Tahara J; Iwasaki F; Miyagawa N; Goto H; Imashuku S; Hosoi H
Int J Hematol; 2018 Dec; 108(6):665-669. PubMed ID: 30143999
[TBL] [Abstract][Full Text] [Related]
4. Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia.
Vetro C; Haferlach T; Meggendorfer M; Stengel A; Jeromin S; Kern W; Haferlach C
Cancer Genet; 2020 Jan; 240():15-22. PubMed ID: 31698332
[TBL] [Abstract][Full Text] [Related]
5. GAS6 Oncogene and Reverse MLLT3-KMT2A Duplications in an Infant with Acute Myeloid Leukemia and a Novel Complex Hyperdiploid Karyotype: Detailed High-Resolution Molecular Cytogenetic Studies.
Capela de Matos RR; Ney Garcia DR; Cifoni E; Othman MAK; Tavares de Souza M; Carboni EK; Ferreira GM; Liehr T; Ribeiro RC; M Silva ML
Cytogenet Genome Res; 2017; 152(1):33-37. PubMed ID: 28595195
[TBL] [Abstract][Full Text] [Related]
6. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/
Bill M; Mrózek K; Kohlschmidt J; Eisfeld AK; Walker CJ; Nicolet D; Papaioannou D; Blachly JS; Orwick S; Carroll AJ; Kolitz JE; Powell BL; Stone RM; de la Chapelle A; Byrd JC; Bloomfield CD
Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26340-26346. PubMed ID: 33020282
[TBL] [Abstract][Full Text] [Related]
7. Whole transcriptome sequencing reveals a KMT2A-USP2 fusion in infant acute myeloid leukemia.
Ikeda J; Shiba N; Tsujimoto SI; Yoshida M; Nakabayashi K; Ogata-Kawata H; Okamura K; Takeuchi M; Osumi T; Tomizawa D; Hata K; Kiyokawa N; Ito S; Kato M
Genes Chromosomes Cancer; 2019 Sep; 58(9):669-672. PubMed ID: 30869817
[TBL] [Abstract][Full Text] [Related]
8. Therapy-induced Deletion in 11q23 Leading to Fusion of
Panagopoulos I; Andersen K; Eilert-Olsen M; Zeller B; Munthe-Kaas MC; Buechner J; Osnes LTN; Micci F; Heim S
Cancer Genomics Proteomics; 2021; 18(1):67-81. PubMed ID: 33419897
[TBL] [Abstract][Full Text] [Related]
9. A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia.
Harada T; Heshmati Y; Kalfon J; Perez MW; Xavier Ferrucio J; Ewers J; Hubbell Engler B; Kossenkov A; Ellegast JM; Yi JS; Bowker A; Zhu Q; Eagle K; Liu T; Kai Y; Dempster JM; Kugener G; Wickramasinghe J; Herbert ZT; Li CH; Vrabič Koren J; Weinstock DM; Paralkar VR; Nabet B; Lin CY; Dharia NV; Stegmaier K; Orkin SH; Pimkin M
Genes Dev; 2022 Mar; 36(5-6):368-389. PubMed ID: 35301220
[TBL] [Abstract][Full Text] [Related]
10. The stem cell-specific long noncoding RNA HOXA10-AS in the pathogenesis of KMT2A-rearranged leukemia.
Al-Kershi S; Bhayadia R; Ng M; Verboon L; Emmrich S; Gack L; Schwarzer A; Strowig T; Heckl D; Klusmann JH
Blood Adv; 2019 Dec; 3(24):4252-4263. PubMed ID: 31867596
[TBL] [Abstract][Full Text] [Related]
11. C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiation.
Marneth AE; Prange KHM; Al Hinai ASA; Bergevoet SM; Tesi N; Janssen-Megens EM; Kim B; Sharifi N; Yaspo ML; Kuster J; Sanders MA; Stoetman ECG; Knijnenburg J; Arentsen-Peters TCJM; Zwaan CM; Stunnenberg HG; van den Heuvel-Eibrink MM; Haferlach T; Fornerod M; Jansen JH; Valk PJM; van der Reijden BA; Martens JHA
Leukemia; 2018 Mar; 32(3):828-836. PubMed ID: 28871137
[TBL] [Abstract][Full Text] [Related]
12. Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia.
van Weelderen RE; Harrison CJ; Klein K; Jiang Y; Abrahamsson J; Alonzo T; Aplenc R; Arad-Cohen N; Bart-Delabesse E; Buldini B; De Moerloose B; Dworzak MN; Elitzur S; Fernández Navarro JM; Gamis A; Gerbing RB; Goemans BF; de Groot-Kruseman HA; Guest E; Ha SY; Hasle H; Kelaidi C; Lapillonne H; Leverger G; Locatelli F; Miyamura T; Norén-Nyström U; Polychronopoulou S; Rasche M; Rubnitz JE; Stary J; Tierens A; Tomizawa D; Zwaan CM; Kaspers GJL
Blood Adv; 2024 Jun; 8(12):3200-3213. PubMed ID: 38621200
[TBL] [Abstract][Full Text] [Related]
13. De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia.
Hyrenius-Wittsten A; Pilheden M; Sturesson H; Hansson J; Walsh MP; Song G; Kazi JU; Liu J; Ramakrishan R; Garcia-Ruiz C; Nance S; Gupta P; Zhang J; Rönnstrand L; Hultquist A; Downing JR; Lindkvist-Petersson K; Paulsson K; Järås M; Gruber TA; Ma J; Hagström-Andersson AK
Nat Commun; 2018 May; 9(1):1770. PubMed ID: 29720585
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan.
Miyamura T; Kudo K; Tabuchi K; Ishida H; Tomizawa D; Adachi S; Goto H; Yoshida N; Inoue M; Koh K; Sasahara Y; Fujita N; Kakuda H; Noguchi M; Hiwatari M; Hashii Y; Kato K; Atsuta Y; Okamoto Y
Leuk Res; 2019 Dec; 87():106263. PubMed ID: 31707119
[TBL] [Abstract][Full Text] [Related]
15. Recurrent
Matsuo H; Yoshida K; Fukumura K; Nakatani K; Noguchi Y; Takasaki S; Noura M; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Okada A; Nannya Y; Takeda J; Ueno H; Shiba N; Yamato G; Handa H; Ono Y; Hiramoto N; Ishikawa T; Usuki K; Ishiyama K; Miyawaki S; Itonaga H; Miyazaki Y; Kawamura M; Yamaguchi H; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Hayashi Y; Mano H; Miyano S; Kamikubo Y; Ogawa S; Adachi S
Blood Adv; 2018 Nov; 2(21):2879-2889. PubMed ID: 30381403
[TBL] [Abstract][Full Text] [Related]
16. SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.
Di Mambro A; Arroyo-Berdugo Y; Fioretti T; Randles M; Cozzuto L; Rajeeve V; Cevenini A; Austin MJ; Esposito G; Ponomarenko J; Lucas CM; Cutillas P; Gribben J; Williams O; Calle Y; Patel B; Esposito MT
Oncogene; 2023 Dec; 42(50):3670-3683. PubMed ID: 37891368
[TBL] [Abstract][Full Text] [Related]
17. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
Pollard JA; Guest E; Alonzo TA; Gerbing RB; Loken MR; Brodersen LE; Kolb EA; Aplenc R; Meshinchi S; Raimondi SC; Hirsch B; Gamis AS
J Clin Oncol; 2021 Oct; 39(28):3149-3160. PubMed ID: 34048275
[TBL] [Abstract][Full Text] [Related]
18. Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
Bourgeois W; Cutler JA; Aubrey BJ; Wenge DV; Perner F; Martucci C; Henrich JA; Klega K; Nowak RP; Donovan KA; Boileau M; Wen Y; Hatton C; Apazidis AA; Olsen SN; Kirmani N; Pikman Y; Pollard JA; Perry JA; Sperling AS; Ebert BL; McGeehan GM; Crompton BD; Fischer ES; Armstrong SA
Blood; 2024 Apr; 143(15):1513-1527. PubMed ID: 38096371
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.
Juul-Dam KL; Shukla NN; Cooper TM; Cuglievan B; Heidenreich O; Kolb EA; Rasouli M; Hasle H; Zwaan CM
Eur J Med Genet; 2023 Dec; 66(12):104869. PubMed ID: 38174649
[TBL] [Abstract][Full Text] [Related]
20. Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23/KMT2A rearrangements.
Yuen KY; Liu Y; Zhou YZ; Wang Y; Zhou DH; Fang JP; Xu LH
Cancer Med; 2023 Jan; 12(2):1418-1430. PubMed ID: 35833755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]